ArticleHormones (Athens, Greece)2025
Sexual dysfunction in male patients with obesity: is it still being overlooked?
Article in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionObesity has been linked to an elevated susceptibility to development of erectile dysfunction, yet the interplay between sex hormone levels, sexual function, and obesity remains unclear. This study aimed to investigate sexual dysfunction among male patients with obesity and to emphasize the importance of recognizing the problem and pursuing solutions.
methodsA total of 60 patients were included in the study (30 patients from the obesity center and 30 patients without obesity as the control group). Assessment of androgen hormone deficiency and erectile dysfunction was conducted through the implementation of AMS and IIEF-5 tests. The questionnaire includes aspects of medical history, demographic features, and lifestyle factors. Comprehensive measurements included BMI, WC, BP, lipid panel, total/free testosterone, sex-hormone-binding-globulin (SHBG), dehydroepiandrosterone-sulfate (DHEAS), fasting blood glucose (FBG), fasting insulin, and HbA1C levels. Results were evaluated using SPSS.
resultsThe AMS score in the obesity group was significantly lower compared to the group without obesity. The IIEF-5 score did not exhibit a statistically significant difference between the groups. Testosterone, free testosterone, SHBG, and HDL values were lower in the obesity group compared to the group without obesity.
conclusionAlthough conducted in a small sample, our findings strongly indicate a positive correlation between obesity and the risk of moderate to severe ED. Most of the time, this condition goes unarticulated, thereby adversely affecting the quality of life for individuals with obesity. Clinicians should pay more attention to patients experiencing sexual dysfunction, especially those with obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.